Press releases
- MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York
- MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder
Key statistics
On Friday, Numinus Wellness Inc (LR23:FRA) closed at 0.0402, 9.24% above its 52-week low of 0.0368, set on May 30, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.0402 |
---|---|
High | 0.0402 |
Low | 0.0402 |
Bid | 0.0314 |
Offer | 0.0565 |
Previous close | 0.0368 |
Average volume | 1.32k |
---|---|
Shares outstanding | 316.46m |
Free float | 304.03m |
P/E (TTM) | -- |
Market cap | 20.57m CAD |
EPS (TTM) | -0.1022 CAD |
Data delayed at least 15 minutes, as of May 31 2024 07:48 BST.
More ▼